Familial Adenomatous Polyposis Medical Services in China

Familial Adenomatous Polyposis (FAP) is a rare, autosomal dominant inherited disorder characterized by the development of hundreds to thousands of colorectal adenomatous polyps, typically beginning in adolescence. Left untreated, these polyps carry an almost 100% lifetime risk of progressing to colorectal cancer—usually by age 40–50. FAP results from germline pathogenic variants in the APC (adenomatous polyposis coli) gene on chromosome 5q21–22, which encodes a tumor suppressor protein critical for regulating β-catenin degradation, cell adhesion, migration, and apoptosis. Loss of functional APC leads to constitutive WNT pathway activation, uncontrolled epithelial proliferation, and rapid adenoma formation throughout the colorectum. A milder variant, attenuated FAP (AFAP), presents with fewer polyps (typically 10–100), later onset (mean age ~55), and lower—but still significantly elevated—cancer risk. Epidemiologically, FAP affects approximately 1 in 7,000 to 1 in 22,000 individuals worldwide, with no ethnic or gender predilection; about 25–30% of cases arise from de novo mutations, meaning affected individuals may be the first in their family with the condition. Key risk factors include having a first-degree relative with FAP (conferring 50% inheritance risk) and confirmed APC mutation status. Extracolonic manifestations are common and clinically significant: duodenal and periampullary adenomas (present in up to 90% of adults with FAP, with 3–5% lifetime risk of duodenal cancer), gastric fundic gland polyps, osteomas, dental anomalies, congenital hypertrophy of the retinal pigment epithelium (CHRPE), desmoid tumors (occurring in 10–20%, often post-surgery and potentially life-threatening due to local invasion), and increased risks of thyroid (especially papillary), brain (medulloblastoma in Turcot syndrome variant), and hepatoblastoma (in young children). Quality of life is profoundly impacted—not only by the psychological burden of lifelong surveillance, high cancer anxiety, and prophylactic surgery decisions, but also by physical consequences: colectomy often necessitates ileorectal anastomosis (IRA) or restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA), both associated with bowel frequency, urgency, nocturnal seepage, sexual dysfunction, and infertility concerns (particularly in women after IPAA or desmoid-related pelvic surgery). Desmoid disease can cause chronic pain, organ compression, and functional impairment. Genetic counseling, early endoscopic screening starting at age 10–12, and timely surgical intervention remain cornerstones of management. With comprehensive care—including genetic testing, coordinated gastroenterology, surgical oncology, and psychosocial support—life expectancy approaches normal, though lifelong multidisciplinary follow-up is essential.

Familial Adenomatous Polyposis (FAP) is an autosomal dominant inherited disorder caused by germline pathogenic variants in the APC gene, characterized by the development of hundreds to thousands of colorectal adenomatous polyps beginning in adolescence. Without intervention, the cumulative risk of colorectal cancer approaches 100% by age 40–50. Management requires a multidisciplinary, lifelong strategy coordinated primarily by gastroenterology, surgical oncology, and genetic counseling services. Treatment encompasses surveillance, chemoprevention, endoscopic management, and definitive surgical resection—tailored to disease burden, genotype-phenotype correlations, patient age, and comorbidities.

Conservative treatment in FAP centers on rigorous endoscopic surveillance and risk mitigation rather than curative intent. Colonoscopy should commence at age 10–12 years, repeated annually until polyposis is evident; once dense polyposis develops (typically >20–30 adenomas or large (>6 mm) or dysplastic lesions), prophylactic colectomy is strongly recommended. Upper gastrointestinal surveillance—including esophagogastroduodenoscopy (EGD)—begins at age 20–25 and is repeated every 1–5 years depending on duodenal polyp burden (Spigelman stage). Surveillance for extracolonic manifestations—including fundic gland polyps, gastric adenomas, periampullary adenomas, desmoid tumors, thyroid carcinoma, and brain tumors (Turcot syndrome)—is integral. Lifestyle modifications—including smoking cessation, limiting red/processed meat intake, maintaining healthy BMI, and regular physical activity—are advised to reduce secondary carcinogenic stimuli, though evidence for their impact on polyp progression remains observational.

Pharmacologic intervention serves as adjunctive chemoprevention, not replacement for surgery. Nonsteroidal anti-inflammatory drugs (NSAIDs), particularly sulindac and celecoxib, have demonstrated efficacy in reducing colorectal and duodenal polyp number and size in randomized controlled trials. Sulindac (200 mg twice daily) reduces rectal polyp burden by ~30–50% in patients with retained rectum post-colectomy (e.g., after ileorectal anastomosis), while celecoxib (400 mg twice daily) showed significant regression of duodenal adenomas in FAP patients in the APC trial. However, long-term NSAID use carries risks—including gastrointestinal ulceration, renal impairment, and cardiovascular events—and is contraindicated in patients with aspirin hypersensitivity or advanced renal disease. Aspirin has shown modest benefit in sporadic adenoma prevention but lacks robust FAP-specific data. Emerging agents—including COX-2 inhibitors combined with EGFR inhibitors (e.g., erlotinib) and novel Wnt pathway modulators—are under investigation in early-phase trials but remain investigational outside clinical research settings.

Surgical treatment remains the cornerstone of FAP management. Total proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the preferred procedure for most patients with established polyposis, offering near-complete elimination of colorectal cancer risk while preserving continence and avoiding a permanent stoma. Alternative options include total colectomy with ileorectal anastomosis (IRA), reserved for select patients with minimal rectal polyp burden (<5–10 small adenomas) and excellent compliance with lifelong rectal surveillance. IRA carries a 10–25% cumulative risk of rectal cancer over 20 years and mandates annual high-definition rectoscopy. For patients with severe desmoid disease, unresectable duodenal polyposis, or contraindications to IPAA, total proctocolectomy with end-ileostomy may be indicated. Prophylactic gastroduodenectomy is rarely performed but considered for Spigelman stage IV disease unresponsive to endoscopic therapy. All surgical candidates require preoperative genetic confirmation, comprehensive upper GI evaluation, and assessment for desmoid tumor risk (e.g., family history, APC mutation location—codon 1444–1578 confers higher desmoid risk).

China offers distinct advantages in FAP care, particularly through its integrated national screening infrastructure and rapidly advancing endoscopic-surgical capabilities. Major academic centers—including Peking Union Medical College Hospital, Zhongshan Hospital (Fudan University), and West China Hospital—operate dedicated hereditary gastrointestinal cancer clinics with standardized protocols aligned with international guidelines (ESMO, NCCN, ESGE). High-volume endoscopy units routinely perform advanced techniques such as chromoendoscopy, narrow-band imaging (NBI), and endoscopic mucosal resection (EMR) for duodenal and gastric adenomas. Robotic-assisted IPAA is increasingly available in tier-1 hospitals, demonstrating reduced intraoperative blood loss and shorter hospital stays compared to laparoscopic approaches in recent cohort studies. Moreover, China’s National Medical Products Administration (NMPA) has expedited approval pathways for targeted therapies and biosimilars, improving access to celecoxib and enabling participation in global phase II/III trials of Wnt inhibitors. Genetic testing turnaround time has decreased to <14 days in accredited laboratories, facilitating timely risk stratification. Importantly, China’s tiered healthcare system enables seamless referral from community health centers to provincial cancer hospitals, ensuring continuity across surveillance, surgery, and long-term follow-up.

Post-treatment recovery necessitates structured, lifelong follow-up. After IPAA, patients undergo pouchoscopy at 6–12 months, then every 1–3 years depending on pouch inflammation or dysplasia. IRA patients require annual high-definition rectoscopy with random biopsies. Duodenal surveillance continues every 6–12 months for Spigelman stage III–IV, with endoscopic ampullectomy or endoscopic retrograde cholangiopancreatography (ERCP)-guided interventions for ampullary lesions. Patients should receive annual thyroid ultrasound and abdominal MRI if desmoid risk is elevated. Psychosocial support—including genetic counseling for at-risk relatives and fertility counseling (especially pre-IPAA, given potential impact on pelvic anatomy)—is essential. Nutritional guidance focuses on hydration, soluble fiber supplementation (e.g., psyllium) to regulate pouch function, and avoidance of excessive caffeine/alcohol that may exacerbate pouchitis. Pregnancy counseling is recommended for women of childbearing age, as desmoid tumors may flare during gestation. Finally, cascade genetic testing of first-degree relatives is mandatory: APC testing should begin at age 10, with colonoscopy initiation by age 12 regardless of test result if testing is declined or unavailable. Adherence to this comprehensive, individualized framework significantly reduces mortality and optimizes quality of life in FAP.